Clinical Trials
3 trialsNCT03643107 2025-01-23
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Allarity Therapeutics
Phase 2 Completed
NCT00124566 2016-01-18
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Eisai Inc.
Phase 2 Completed
NCT00003390 2013-06-21
6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed